《新股消息》RNA技術公司Mirxes完成D輪融資 向港交所提交上市申請
新加坡RNA技術公司Mirxes宣佈成功完成D輪融資,融資總額5,000萬美元,資金將加速Mirxes癌症早篩管線的研發,並大力推動公司在亞太主要市場的商業化。
D輪融資得到了新老投資者的大力支持,其中包括浙江安吉經濟開發區管理委員會的下屬基金與復樸資本,新加坡經濟發展局投資私人有限公司(由新加坡經濟發展局全資擁有,簡稱EDBI),新加坡科技研究局(新加坡貿工部下屬公共研發機構),在日本多家證券交易所上市的三井物產株式會社以及諾輝創投基金。
Mirxes聯合創始人兼首席執行官周礪寒稱,在充滿挑戰的宏觀環境下完成新一輪融資,進一步體現了公司行業領先的miRNA檢測技術平臺對於解決癌症的臨牀和社會經濟負擔的意義,並持續奠定Mirxes在全球癌症早篩技術領域的領導地位。
Mirxes同時宣佈已根據《香港交易所證券上市規則》第18A章的規定向港交所(000388.HK)提交A1上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.